ライフサイエンスコーパス: pleconaril

1 bitor previously under clinical development (pleconaril).

2 , ribavirin, and the anti-picornaviral agent pleconaril.

3 This density could be displaced by pleconaril.

4 Subjects received either pleconaril 200 mg twice daily (initial dose of 400 mg) o

5 al structures of EV-D68 and its complex with pleconaril, a capsid-binding compound that had been deve

6 nd study assessed the efficacy and safety of pleconaril, a novel antiviral drug with broad-spectrum a

7 studies showing that the antiviral effect of pleconaril against HRV16 is greater on the infectivity o

8 Pleconaril and AG7088 have shown the most promise and ar

9 -onset T1D received antiviral treatment with pleconaril and ribavirin (n = 47) or placebo (n = 49) fo

10 the serum C-peptide AUC being higher in the pleconaril and ribavirin treatment group compared to the

11 Viral inhibitors, such as pleconaril and vapendavir, target conserved regions in t

12 h small-molecule antiviral compounds such as pleconaril bind and inhibit functions associated with th

13 irus 16 (HRV16) and HRV14 are incubated with pleconaril, drug occupancy in the binding pocket is lowe

14 Other potentially useful treatments, such as pleconaril for enteroviral meningoencephalitis are under

15 hese data support the safety and efficacy of pleconaril in decreasing the signs and symptoms and vira

16 ation adjacent to the likely binding site of pleconaril in these isolates.

17 elates strongly with virus susceptibility to pleconaril inhibition.

18 e development of capsid-function inhibitors (pleconaril), inhibitors of 3C protease (AG7088), and rec

19 We also showed that pleconaril inhibits EV-D68 at a half-maximal effective c

20 Pleconaril is a broad-spectrum antirhinovirus and antien

21 ncy in the binding pocket is lower than when pleconaril is introduced during assembly prior to crysta

22 s after receiving the initial dose of either pleconaril or placebo, subjects were inoculated intranas

23 he virus developed reduced susceptibility to pleconaril, precluding the in-vivo use of this drug.

24 istant RVs using RV-B5 (1 of the 7 naturally pleconaril-resistant rhinoviruses) and OBR-5-340, a bioa

25 cently developed pyrazolopyrimidines inhibit pleconaril-resistant RVs and EVs, and computational mode

26 We studied the mechanism of inhibition of pleconaril-resistant RVs using RV-B5 (1 of the 7 natural

27 Ten independently derived pleconaril-resistant variants of coxsackievirus B3 were

28 The study results indicate that pleconaril-resistant virus variants are attenuated and s

29 HRV16 than in HRV14 and is more marked with pleconaril than with other compounds.

30 spiratory illness symptom scores (P=.013) in pleconaril-treated as compared with placebo-treated subj

31 Pleconaril (VP 63843) is a novel orally bioavailable sma

32 om patients enrolled in clinical trials with pleconaril were distinct from those that confer natural